Your browser doesn't support javascript.
loading
Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes.
Yang, Jennie H M; Cutler, Antony J; Ferreira, Ricardo C; Reading, James L; Cooper, Nicholas J; Wallace, Chris; Clarke, Pamela; Smyth, Deborah J; Boyce, Christopher S; Gao, Guo-Jian; Todd, John A; Wicker, Linda S; Tree, Timothy I M.
Afiliación
  • Yang JH; Department of Immunobiology, Faculty of Life Sciences & Medicine, King's College London, London, U.K. National Institute of Health Research Biomedical Research Centre at Guy's and St Thomas' National Health Service Foundation Trust and King's College London, London, U.K. timothy.tree@kcl.ac.uk j
  • Cutler AJ; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.
  • Ferreira RC; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.
  • Reading JL; Department of Immunobiology, Faculty of Life Sciences & Medicine, King's College London, London, U.K. National Institute of Health Research Biomedical Research Centre at Guy's and St Thomas' National Health Service Foundation Trust and King's College London, London, U.K.
  • Cooper NJ; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.
  • Wallace C; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.
  • Clarke P; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.
  • Smyth DJ; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.
  • Boyce CS; BD Biosciences, Cell Analysis, San Diego, CA.
  • Gao GJ; BD Biosciences, Cell Analysis, San Diego, CA.
  • Todd JA; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.
  • Wicker LS; JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, U.K.
  • Tree TI; Department of Immunobiology, Faculty of Life Sciences & Medicine, King's College London, London, U.K. National Institute of Health Research Biomedical Research Centre at Guy's and St Thomas' National Health Service Foundation Trust and King's College London, London, U.K. timothy.tree@kcl.ac.uk j
Diabetes ; 64(11): 3891-902, 2015 Nov.
Article en En | MEDLINE | ID: mdl-26224887
ABSTRACT
Defective immune homeostasis in the balance between FOXP3+ regulatory T cells (Tregs) and effector T cells is a likely contributing factor in the loss of self-tolerance observed in type 1 diabetes (T1D). Given the importance of interleukin-2 (IL-2) signaling in the generation and function of Tregs, observations that polymorphisms in genes in the IL-2 pathway associate with T1D and that some individuals with T1D exhibit reduced IL-2 signaling indicate that impairment of this pathway may play a role in Treg dysfunction and the pathogenesis of T1D. Here, we have examined IL-2 sensitivity in CD4+ T-cell subsets in 70 individuals with long-standing T1D, allowing us to investigate the effect of low IL-2 sensitivity on Treg frequency and function. IL-2 responsiveness, measured by STAT5a phosphorylation, was a very stable phenotype within individuals but exhibited considerable interindividual variation and was influenced by T1D-associated PTPN2 gene polymorphisms. Tregs from individuals with lower IL-2 signaling were reduced in frequency, were less able to maintain expression of FOXP3 under limiting concentrations of IL-2, and displayed reduced suppressor function. These results suggest that reduced IL-2 signaling may be used to identify patients with the highest Treg dysfunction and who may benefit most from IL-2 immunotherapy.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T Reguladores / Diabetes Mellitus Tipo 1 / Subunidad alfa del Receptor de Interleucina-2 Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Diabetes Año: 2015 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T Reguladores / Diabetes Mellitus Tipo 1 / Subunidad alfa del Receptor de Interleucina-2 Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Diabetes Año: 2015 Tipo del documento: Article
...